The Conversation (0)
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569
Mar. 27, 2018 09:03AM PST
Biotech InvestingArch Biopartners (TSXV:ARCH) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and methods of use of its lead anti-bacterial drug candidate, AB569. The new U.S. patent is titled, “Compositions and Methods for Treating Bacterial Infection” and has been issued to the University of Cincinnati, which previously granted …
Arch Biopartners (TSXV:ARCH) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and methods of use of its lead anti-bacterial drug candidate, AB569. The new U.S. patent is titled, “Compositions and Methods for Treating Bacterial Infection” and has been issued to the University of Cincinnati, which previously granted an exclusive commercial license to Arch on all patents related to AB569.
As quoted in the press release:
“This patent issuance, which protects the composition of AB569, gives Arch a stronger commercial position to pursue treating not just CF patients, but also the millions of other patients that have chronic antibiotic resistant lung infections including those with COPD. It also opens the door for Arch to develop treatments for many other indications where antibiotic resistance is a problem, such as urinary tract infections and wound care,” said Richard Muruve, CEO of Arch.